Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Ophthotech

- PMLiVE

Novartis to relocate UK headquarters to London’s White City

Emerging life sciences hub has already attracted Autolus

Bayer symbol

Loxo, Bayer get FDA okay for biomarker-driven cancer drug

A first for Loxo, and a second mutation-based targeted drug

- PMLiVE

Novartis gets EU nod for Luxturna gene therapy

Approval comes almost a year after it was secured a green light in the US

Roche Basel Switzerland

Roche builds on Immunocore ImmTAC deal

Extends partnership to target MAGE-A4 protein tumours

- PMLiVE

Roche gains speedy review for Tecentriq in first-line breast cancer

Set to become the first immunotherapy for triple negative breast cancer

- PMLiVE

Novartis’ heart failure drug Entresto proves superior to enalapril

Results could see the drug strengthen its position in the market

Roche Basel Switzerland

Roche and AbbVie prepare to move Venclexta into first-line CLL

Data shows an extended PFS compared to those on Gazyva plus chlorambucil chemo

- PMLiVE

Novartis culls pipeline to focus on most transformative science

Anti-infectives among areas hit by streamlining

- PMLiVE

Novartis and Pfizer to collaborate on NASH combinations

Big pharma giants target nascent multi-billion market

Pharma: in search of the sustainable ‘win win’ with the NHS

Fiona Bride on how Novartis is responding to new models of care

- PMLiVE

Novartis gains label boost for Cosentyx

Updated label allows dosing flexibility of up to 300mg

- PMLiVE

Roche’s new flu pill Xofluza approved in US

First novel treatment in decades, but hasn't shown superiority to Tamiflu

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links